• Hsiangkuo Yuan and Tzu-Ying Chuang.
• Jefferson Headache Center, Department of Neurology, Thomas Jefferson University Hospital, 900 Walnut St. Suite 200, PA, 19107, Philadelphia, USA. hsiangkuo.yuan@jefferson.edu.
• Curr Pain Headache Rep. 2021 Nov 11; 25 (11): 71.

Purpose Of ReviewNeuromodulation devices have become an attractive alternative to traditional pharmacotherapy for migraine, especially for patients intolerant to medication or who prefer non-pharmacological options. In the past decades, many studies demonstrated the efficacy of neuromodulation devices in patients with episodic migraine (EM). However, the benefit of these devices on chronic migraine (CM), which is typically more debilitating and refractory than EM, remains not well studied.Recent FindingsWe reviewed the literature within the last five years on using FDA-cleared and investigational devices for CM. There were eight randomized controlled trials and 15 open-label observational studies on ten neuromodulation devices. Neuromodulation is promising for use in CM, although efficacy varies among devices or individuals. Noninvasive devices are usually considered safe with minimal adverse events. However, stimulation protocol and methodology differ between studies. More well-designed studies adhering to the guideline may facilitate FDA clearance and better insurance coverage.© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

8 keywords...

hide…